Soticlestat is in clinical development as an adjunctive therapy in patients with Dravet syndrome, a rare neurological condition characterized by treatment-resistant epilepsy, intellectual disability, and a spectrum of associated conditions such as behaviour, speech, feeding and mobility difficulties. Typically, Dravet syndrome involves multiple, frequent, and often prolonged seizures that do not respond well to treatment. Additionally, after the first year of life, a child’s development may slow down or regress. Children with the condition have an 85% likelihood of surviving into adulthood. However, children with the condition face a significant risk of seizure-related premature mortality, known as sudden unexpected death in epilepsy.
Soticlestat as an adjunctive therapy in patients with Dravet syndrome
Soticlestat is in clinical development as an adjunctive therapy in patients with Dravet syndrome, a rare neurological condition characterized by treatment-resistant epilepsy, intellectual disability, and a spectrum of associated conditions such as behaviour, speech, feeding and mobility difficulties.